IL18 and neoplasm: DCs are a main orchestrator of anti-tumor immune responses, and the effects of their interactions with NK cells in the TME on anti-tumor immunity have been extensively reviewed.156,264 DCs can activate NK cells by producing IL-12, IL-15, and IL-18, thus enhancing anti-tumor activity.265–267 Generating CXCL9 and CXCL10 to recruit effector T cells is also part of DCs’ anti-tumor repertoire.268 However, whether CXCL9 and CXCL10 produced by DCs have the same effect on NK cells during disease states needs to be verified.